A Phase II / III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Inclusion Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
- Patients must have known BRAF mutational status of tumor; wild-type (WT) or mutated, prior to randomization
- Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception or to abstain from sexual intercourse for at least one week prior to the start of the research study, and continuing for 5 months for women of childbearing potential and 7 months for sexually active males after the last dose of the study drugs
- Patients must have unresectable stage III or stage IV melanoma; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive
- Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization
- Patients may have had prior systemic therapy in the adjuvant setting (e.g. interferon, BRAF, or mitogen-activated protein kinase [MEK] agents); patients may have had prior anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment; patients may not have had any prior programmed cell death (PD)-1/PD-ligand (PD-L)1 agent in the adjuvant setting
- Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to randomization and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 4 weeks from randomization and patients must be fully recovered from post-surgical complications
- White blood count >= 3,000/uL (obtained within 4 weeks prior to randomization)
- Absolute neutrophil count (ANC) >= 1,500/uL (obtained within 4 weeks prior to randomization)
- Platelet count >= 100,000/uL (obtained within 4 weeks prior to randomization)
- Hemoglobin >= 9 g/dL (obtained within 4 weeks prior to randomization)
- Serum creatinine =< 1.5 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) >= 40 ml/min (obtained within 4 weeks prior to randomization)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases) (obtained within 4 weeks prior to randomization)
- Alkaline phosphatase =< 2 x ULN (=< 5 x ULN for patients with known liver involvement and =< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks prior to randomization)
- Total bilirubin =< 1.5 x ULN except subjects with normal direct bilirubin or those with known Gilbert’s syndrome (obtained within 4 weeks prior to randomization)
- Serum lactate dehydrogenase (LDH) =< 10 X ULN (obtained within 4 weeks prior to randomization)
- Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
Exclusion Criteria
- Women must not be pregnant or breast-feeding due to use of cytotoxic immunotherapy and risk of teratogenic side effects; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting
- Patients must not receive any other investigational agents while on study or within four weeks prior to randomization
- Patients are excluded for receiving any non-oncology vaccine therapy used for prevention of infectious diseases for up to four weeks (28 days) prior to or after any dose of ipilimumab; NOTE: Patients are permitted to receive the seasonal influenza vaccine; if seasonal influenza vaccine is considered, killed vaccines should be recommended
- Patients are ineligible if they have any currently active central nervous system (CNS) metastases; patients who have treated brain metastases (with either surgical resection or stereotactic radiosurgery) that have been stable on head magnetic resonance imaging (MRI) or contrast computed tomography (CT) scan for at least 4 weeks following treatment and within 4 weeks prior to randomization are eligible; patients must not have taken any steroids =< 14 days prior to randomization for the purpose of managing their brain metastases; patients with only whole brain irradiation for treatment of CNS metastases will be ineligible
- Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for > 3 years prior to the time of randomization
- Patients must not have any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), including but not limited to, ongoing or active infection requiring parenteral antibiotics on day 1, history of bleeding diathesis or need for concurrent anticoagulation (international normalized ratio [INR] =< 1.5 and partial thromboplastin time [PTT] within 1.1 x ULN), or psychiatric illness/social situations that would limit compliance with study requirements, interfere with subject’s safety, or obtaining informed consent
- Patients with human immunodeficiency virus (HIV) infection are ineligible; due to the mechanism of action of ipilimumab and GM-CSF, activity and side effects in an immune compromised patient are unknown
- Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible; patients with cleared HBV and HCV (0 viral load) infection will be allowed
- Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study
- Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis [e.g., Wegener’s granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis); other CNS autoimmune disease (e.g., multiple sclerosis)
- Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
- Patients must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment that in the opinion of the investigator may interfere with compliance, make the administration of the study drugs hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea; patients must not have an active infection requiring current treatment with parenteral antibiotics
Alabama
Birmingham
Arizona
Kingman
Arkansas
Little Rock
California
Anaheim
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Cameron Park
Castro Valley
Davis
Duarte
Dublin
Fontana
Fremont
Fresno
Harbor City
Irvine
Los Angeles
Modesto
Mountain View
Novato
Oakland
Ontario
Orange
Palo Alto
Panorama City
Richmond
Riverside
Roseville
Sacramento
San Diego
San Francisco
San Jose
San Leandro
San Marcos
San Mateo
San Rafael
Santa Clara
Santa Cruz
Santa Rosa
Stockton
Sunnyvale
Upland
Vacaville
Vallejo
Walnut Creek
Woodland Hills
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Greeley
Lafayette
Lakewood
Lone Tree
Longmont
Loveland
Pueblo
Wheat Ridge
Connecticut
Guilford
Hartford
New Haven
District of Columbia
Washington
Florida
Coral Gables
Deerfield Beach
Fort Lauderdale
Miami
Plantation
Georgia
Athens
Atlanta
Augusta
Cumming
Decatur
Duluth
Lawrenceville
Savannah
Hawaii
Aiea
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Meridian
Nampa
Post Falls
Sandpoint
Illinois
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Glenview
Highland Park
Kewanee
Macomb
Mattoon
O'Fallon
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Yorkville
Indiana
Evansville
Indianapolis
Michigan City
Mooresville
Newburgh
Iowa
Ames
Boone
Fort Dodge
Jefferson
Marshalltown
Sioux City
Kansas
Chanute
Dodge City
El Dorado
Fort Scott
Independence
Kingman
Lawrence
Liberal
Manhattan
McPherson
Newton
Parsons
Pratt
Salina
Wellington
Wichita
Winfield
Kentucky
Crestview Hills
Louisville
Louisiana
Baton Rouge
Covington
Houma
Kenner
Monroe
New Orleans
Shreveport
Maine
Bangor
Brewer
Kennebunk
Scarborough
Maryland
Baltimore
Cumberland
Randallstown
Massachusetts
Boston
Springfield
Worcester
Michigan
Adrian
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Dearborn
Detroit
East China
Flint
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Monroe
Muskegon
Norton Shores
Pontiac
Reed City
Rochester Hills
Royal Oak
Saginaw
Sterling Heights
Tawas City
Traverse City
Troy
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Bemidji
Brainerd
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maplewood
Minneapolis
Park Rapids
Robbinsdale
Saint Paul
Sandstone
Shakopee
Stillwater
Thief River Falls
Virginia
Waconia
Woodbury
Worthington
Missouri
Bonne Terre
Cape Girardeau
Farmington
Jefferson City
Saint Joseph
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Nebraska
North Platte
Omaha
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Lebanon
New Jersey
Hackensack
New Mexico
Albuquerque
Rio Rancho
Santa Fe
New York
Buffalo
Cooperstown
New York
Rochester
North Carolina
Asheville
Clinton
Goldsboro
Hendersonville
Jacksonville
Kenansville
Kinston
Richlands
North Dakota
Bismarck
Fargo
Jamestown
Ohio
Beachwood
Centerville
Cincinnati
Cleveland
Columbus
Dayton
Fairfield
Findlay
Franklin
Greenville
Kettering
Maumee
Mentor
Middletown
Newark
Oregon
Portsmouth
Sandusky
Sidney
Sylvania
Toledo
Troy
West Chester
Oklahoma
Oklahoma City
Oregon
Baker City
Ontario
Pennsylvania
Allentown
Beaver
Bethlehem
Danville
East Stroudsburg
Greensburg
Hazleton
Johnstown
Lewisburg
Lewistown
McKeesport
Moon Township
Pittsburgh
Pottsville
Sayre
Scranton
Selinsgrove
Seneca
State College
Uniontown
Washington
West Reading
Wilkes-Barre
Williamsport
South Carolina
Bluffton
Greenville
Hilton Head Island
South Dakota
Sioux Falls
Tennessee
Franklin
Knoxville
Nashville
Oak Ridge
Texas
Dallas
Utah
Farmington
Salt Lake City
South Jordan
Vermont
Burlington
Virginia
Charlottesville
Fredericksburg
Lynchburg
Richmond
Winchester
Washington
Bellevue
Renton
West Virginia
Huntington
Wisconsin
Antigo
Ashland
Burlington
Chippewa Falls
Eau Claire
Fond Du Lac
Germantown
Grafton
Green Bay
Johnson Creek
Kenosha
La Crosse
Madison
Marinette
Marshfield
Medford
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
Weston
Wisconsin Rapids
PRIMARY OBJECTIVE:
I. To compare the overall survival (OS) of nivolumab/ipilimumab/sargramostim (GM-CSF) versus nivolumab/ipilimumab.
SECONDARY OBJECTIVES:
I. To evaluate progression free survival (PFS) of patients treated with nivolumab/ipilimumab/GM-CSF versus nivolumab/ipilimumab.
II. To assess for differences in tolerability, specifically the rate of grade III or higher adverse events, between nivolumab/ipilimumab/GM-CSF versus nivolumab/ipilimumab.
III. To evaluate immune-related response rate (based on immune-related response criteria) and response rate (based on Response Evaluation Criteria in Solid Tumors [RECIST] criteria) and to compare them.
EXPLORATORY TOBACCO USE OBJECTIVES:
I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events [both clinical and hematologic] and dose modifications).
II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.
III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.
IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1, ipilimumab IV over 30 minutes on day 1, and sargramostim subcutaneously (SC) on days 1-14. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in induction therapy. Patients with partial response (PR), stable disease (SD), or complete response (CR) at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity.
ARM B: INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive nivolumab as in induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Trial Phase Phase II/III
Trial Type Treatment
Lead Organization
ECOG-ACRIN Cancer Research Group
Principal Investigator
Frank Stephen Hodi
- Primary ID EA6141
- Secondary IDs NCI-2014-02674
- Clinicaltrials.gov ID NCT02339571